NCT07424599

Brief Summary

This current comparative study involved 54 patients undergoing thoracoscopic thymectomy who were distributed randomly into three equal groups to receive ultrasound (US)-guided ESPB using 20 ml bupivacaine 0.25% (group B) , 20 ml bupivacaine 0.25% with 8 mg dexamethasone (group BS), 20 ml bupivacaine 0.25% with dexmedetomidine 1mcg/kg (group BM). The time till the first postoperative rescue analgesic requested was the primary outcome. The secondary outcomes included the postoperative pain scores and analgesic consumption.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
4mo left

Started Mar 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
Mar 2026Sep 2026

First Submitted

Initial submission to the registry

February 15, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 20, 2026

Completed
23 days until next milestone

Study Start

First participant enrolled

March 15, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2026

Last Updated

February 20, 2026

Status Verified

February 1, 2026

Enrollment Period

6 months

First QC Date

February 15, 2026

Last Update Submit

February 15, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • the duration between the surgery end and the 1st rescue analgesia the patient requested.

    24 hours postoperatively

Secondary Outcomes (2)

  • .Total ketorolac consumption

    24 hours postoperatively

  • . Number of patients needed rescue tramadol

    24 hours postoperatively

Study Arms (3)

(group B)

ACTIVE COMPARATOR

ultrasound (US)-guided ESPB using 20 ml bupivacaine 0.25%

Procedure: Erector Spinae Plane Block

Group BS

ACTIVE COMPARATOR

20 ml bupivacaine 0.25% with 8 mg dexamethasone

Procedure: Erector Spinae Plane Block

Group BM

ACTIVE COMPARATOR

20 ml bupivacaine 0.25% with dexmedetomidine 1mcg/kg

Procedure: Erector Spinae Plane Block

Interventions

An echogenic 21 gauge 10 cm needle was introduced in caudo-cephalic orientation utilizing the in-plane approach and traversing through trapezius, rhomboid, and erector spinae muscles till reaching the transverse process then slightly withdrawn and hydrodissection was done by 3 mL of saline 0.9% to verify the accurate implantation of the block needle tip between the erector spinae muscle and the transverse process (the erector spinae plane). Incremental LA injection was verified through US observation for the upward displacement and lifting of erector spinae muscle from the transverse process with craniocaudal spread of the LA in the targeted plane. The LA increments were one ml every 5 seconds with intermittent aspiration every 5 mL to avoid intravascular injection.

(group B)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • myasthenic patients
  • American Society of Anesthesiologists (ASA) physical grade of 2-3)
  • who underwent video assisted thoracoscopic thymectomy

You may not qualify if:

  • Refused participation in the study,
  • known allergy for this study drugs ,
  • Contraindication to the ESPB as infection at block site \& marked chest cage deformity,
  • significant bleeding disorders ,
  • patients with significant renal or liver dysfunction,
  • heart block ,
  • poor ventilatory function,
  • severe chronic obstructive pulmonary disease,
  • morbid obesity,
  • mental disability, or communication difficulties that hindered effective pain assessment,
  • Individuals who was converted to open thoracotomy or those re-explorated for surgical related issues.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisstant professor of anesthesia,intensive care and pain management

Study Record Dates

First Submitted

February 15, 2026

First Posted

February 20, 2026

Study Start

March 15, 2026

Primary Completion (Estimated)

September 15, 2026

Study Completion (Estimated)

September 15, 2026

Last Updated

February 20, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share